奥妥珠单抗或利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗初治弥漫性大B细胞淋巴瘤
GOYA随机III期研究纳入1418例初治晚期弥漫性大B细胞淋巴瘤患者,比较奥妥珠单抗联合CHOP(G-CHOP)与利妥昔单抗联合CHOP(R-CHOP)。中位观察29个月,研究者评估的无进展生存事件两组相似,分层风险比0.92(95%CI 0.76-1.11;P=0.39),3年PFS率分别为70%和67%。G-CHOP未改善PFS,且3-5级不良事件和严重不良事件频率更高。
要点
- G-CHOP与R-CHOP相比未改善初治DLBCL患者的无进展生存。
- G-CHOP组3-5级不良事件73.7% vs R-CHOP组64.7%,严重不良事件42.6% vs 37.6%。
- 探索性亚组分析中,生发中心B细胞样亚型患者PFS优于活化B细胞样亚型,与治疗无关。
核心结论
- 在初治弥漫性大B细胞淋巴瘤患者中,G-CHOP与R-CHOP相比未改善无进展生存。
- 奥妥珠单抗报告的不良事件与已知安全性特征一致。
- 生物标志物分析可能有助于确定奥妥珠单抗在DLBCL中的未来作用。
研究设计与样本
- GOYA是一项随机III期研究,比较G-CHOP与R-CHOP在初治晚期DLBCL患者中的疗效。
- 共纳入1418例患者,随机分配接受8个21天周期的奥妥珠单抗(n=706)或利妥昔单抗(n=712),联合6或8个周期CHOP。
- 主要终点为研究者评估的无进展生存期(PFS)。
主要发现
- 中位观察29个月,研究者评估的PFS事件数G组201例(28.5%)vs R组215例(30.2%),分层风险比0.92(95%CI 0.76-1.11;P=0.39)。
- 3年PFS率G组70% vs R组67%。
- 独立审查的PFS、其他时间-事件终点和肿瘤缓解率两组相似。
- 探索性亚组分析中,生发中心B细胞样亚型患者PFS优于活化B细胞样亚型患者,与治疗无关。
- 3-5级不良事件频率G-CHOP组73.7% vs R-CHOP组64.7%,严重不良事件42.6% vs 37.6%,致死性不良事件5.8% vs 4.3%。
关键数值与推荐
- 最常见不良事件:中性粒细胞减少(G-CHOP 48.3% vs R-CHOP 40.7%)、输注相关反应(36.1% vs 23.5%)、恶心(29.4% vs 28.3%)、便秘(23.4% vs 24.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). Obinutuzumab (G) is a glycoengineered, type II, anti-CD20 monoclonal antibody. GOYA was a randomized phase III study that compared G-CHOP with R-CHOP in patients with previously untreated advanced-stage DLBCL. Methods Patients (N = 1,418) were randomly assigned to receive eight 21-day cycles of G (n = 706) or R (n = 712), plus six or eight cycles of CHOP. Primary end point was investigator-assessed progression-free survival (PFS). Results After median observation of 29 months, the number of investigator-assessed PFS events was similar between G (201; 28.5%) and R (215; 30.2%), stratified hazard ratio was 0.92 (95% CI, 0.76 to 1.11; P = .39), and 3-year PFS rates were 70% and 67%, respectively. Secondary end points of independently reviewed PFS, other time-to-event end points, and tumor response rates were similar between arms. In exploratory subgroup analyses, patients with germinal-center B cell-like subtype had a better PFS than did patients with activated B cell-like subtype, irrespective of treatment. Frequencies of grade 3 to 5 adverse events (AEs; 73.7% v 64.7%, respectively) and serious AEs (42.6% v 37.6%, respectively) were higher with G-CHOP compared with R-CHOP. Fatal AE frequencies were 5.8% for G-CHOP and 4.3% for R-CHOP. The most common AEs were neutropenia (G-CHOP, 48.3%; R-CHOP, 40.7%), infusion-related reactions (G-CHOP, 36.1%; R-CHOP, 23.5%), nausea (G-CHOP, 29.4%; R-CHOP, 28.3%), and constipation (G-CHOP, 23.4%; R-CHOP, 24.5%). Conclusion G-CHOP did not improve PFS compared with R-CHOP in patients with previously untreated DLBCL. AEs reported with G were consistent with the known safety profile. Biomarker analyses may help define a future role for G in DLBCL.
引用
- Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017. PMID: 28796588. doi:10.1200/JCO.2017.73.3402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。